It has been described as “bringing your army right to the enemy.”
There’s a promising new therapy that makes the immune system kill bone marrow cancer cells. It has thus far been successful in as many as 73 percent of patients in two clinical trials, according to a report released by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
The novel therapy, called talquetamab, binds to both T cells and multiple myeloma cells and directs the T cells to exterminate multiple myeloma cells. It has been described as “bringing your army right to the enemy.”
Talquetamab was tested in phase 1 and phase 2 trials.
Luismmolina/iStock.
Talquetamab was tested in phase 1 and phase 2 trials. The study participants had all been previously treated with at least three different therapies without being able to achieve lasting remission.
Comments are closed.